We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPT
51
DELISTED
Opthea Limited American Depositary Shares
OPT
$8.95M 0.11%
2,177,826
-410,819
-16% -$1.29M
NMRA icon
52
Neumora Therapeutics
NMRA
$306M
$8.72M 0.11%
+633,851
New +$10.2M
LONA
53
LeonaBio Inc
LONA
$66.1M
$8.64M 0.11%
315,381
– –
DYN icon
54
Dyne Therapeutics
DYN
$4.15B
$8.09M 0.1%
+285,000
New +$6.45M
PRAX icon
55
Praxis Precision Medicines
PRAX
$8.11B
$8.03M 0.1%
131,533
– –
SAGE
56
DELISTED
Sage Therapeutics
SAGE
$7.63M 0.1%
+407,217
New +$9.39M
SGMT icon
57
Sagimet Biosciences
SGMT
$435M
$7.49M 0.09%
1,381,898
-74,620
-5% -$536K
PRME icon
58
Prime Medicine
PRME
$547M
$7.2M 0.09%
1,028,466
– –
DSGN icon
59
Design Therapeutics
DSGN
$751M
$6.7M 0.08%
1,662,120
+162,120
+11% +$433K
TNGX icon
60
Tango Therapeutics
TNGX
$4.21B
$5.96M 0.07%
750,000
– –
HOOK
61
DELISTED
HOOKIPA Pharma
HOOK
$5.79M 0.07%
812,815
– –
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
$4.87M 0.06%
43,445
– –
MIRM icon
63
Mirum Pharmaceuticals
MIRM
$6.56B
$4.78M 0.06%
190,476
– –
TLIS
64
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$4.45M 0.06%
508,323
– –
PCVX icon
65
Vaxcyte
PCVX
$7.65B
$3.34M 0.04%
48,885
– –
IPSC icon
66
Century Therapeutics
IPSC
$364M
$3.33M 0.04%
797,460
– –
ALPN
67
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.23M 0.04%
+81,578
New +$2.41M
FDMT icon
68
4D Molecular Therapeutics
FDMT
$502M
$3.19M 0.04%
+100,000
New +$2.55M
CYPH
69
Cypherpunk Technologies Inc
CYPH
$64M
$3.12M 0.04%
1,172,175
– –
CMPX icon
70
Compass Therapeutics
CMPX
$349M
$3.08M 0.04%
1,557,630
– –
NAMS icon
71
NewAmsterdam Pharma
NAMS
$3.26B
$2.29M 0.03%
+96,827
New +$1.97M
VTVT icon
72
vTv Therapeutics
VTVT
$124M
$2.29M 0.03%
+97,314
New +$1.24M
KALA icon
73
KALA BIO
KALA
$12.5M
$2.12M 0.03%
5,332
– –
ALGS icon
74
Aligos Therapeutics
ALGS
$26.3M
$2.03M 0.03%
83,056
– –
ELVN icon
75
Enliven Therapeutics
ELVN
$3.78B
$2.02M 0.03%
+114,833
New +$1.76M
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Baker Bros. Advisors held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Baker Bros. Advisors's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Baker Bros. Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Baker Bros. Advisors opened 12 new positions and closed 7 in Q1 2024.
  • Baker Bros. Advisors's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.